秋水仙碱治疗新型冠状病毒肺炎研究  

Colchicine in the treatment of coronavirus disease 2019

作　　者：曹灵 赵天仪 朱小霞 邹和建[1,2] CAO Ling;ZHAO Tianyi;ZHU Xiaoxia;ZOU Hejian(Department of Rheumatology,Huashan Hospital,Fudan University,Shanghai 200040,China;Institute of Rheumatology,Immunology and Allergy,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院风湿免疫科,上海200040 [2]复旦大学风湿免疫过敏性疾病研究中心,上海200040

出　　处：《上海医药》2021年第19期66-69,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：上海申康医院发展中心专科疾病临床“五新”转化项目(16CR3012A);上海申康医院发展中心适宜技术联合开发推广应用项目(SHDC12016227)。

摘　　要：新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)仍在全球肆虐,对其患者除对症处理外,没有有效的治疗措施。目前,COVID-19治疗以抗病毒治疗为主,酌情给予抗炎治疗,但除糖皮质激素外,其他抗炎药物的使用并无明确的依据。秋水仙碱是临床上常用的抗炎药物之一,有研究发现它治疗COVID-19有效,现正在进行多项临床研究。本文介绍秋水仙碱治疗COVID-19有效的可能机制和相关临床研究情况。Coronavirus disease 2019(COVID-19)is still raging around the world and there is no effective therapy for its patients except for the symptomatic treatment.At present,the treatment of COVID-19 is based on antiviral therapy and antiinflammatory treatment is given as appropriate.However,there is no clear basis for the use of other anti-inflammatory drugs except for glucocorticoids.Colchicine is one of the anti-inflammatory drugs commonly used in clinic,studies have found that it is effective in the treatment of COVID-19 and a number of clinical trials are currently underway.This article introduces the possible mechanisms of colchicine for the effective treatment of COVID-19 and the related clinical research status.

关 键 词：秋水仙碱 新型冠状病毒肺炎 临床研究 

分 类 号：R971.1[医药卫生—药品] R512.99[医药卫生—药学]